Investigation of the effect of the incretin on cardiac function in patients with type 2 diabetes

Investigation of the effect of the incretin on cardiac function in patients with type 2 diabetes - Incretin and cardiac function

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014725

Enrollment

Registered

2014-07-31

Start date

2017-07-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

DPP4 inhibitor treatment group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetes

Exclusion criteria

Exclusion criteria: 1) Allergy of Incretin related drug 2) Patients who receive DPP4 inhibitors or GLP-1 before starting study 3) Pregnant, lactating, possibly pregnant or planning to become pregnant women 4) Renal, hepatic, cardiovascular, thyroid, or hematological disease. 5) Malignant tumor 6) Patients considered as inadequate by the principal investigator

Design outcomes

Primary

Measure	Time frame
Change in cardiac function by echocardiography (including speckle tracking)	—

Secondary

Measure	Time frame
1) All cause death, 2)Cardiovascular events (composite of cardiovascular death, non-fatal myocardial infarction, unstable angina pectoris, non-fatal ischemic stroke, hospitalization for heart failure, coronary revascularization, or hospitalization for peripheral artery disease), 3) Change in fasting glucose, HbA1c, body weight, insluin resistance and secretion, BNP, Hs-CRP, lipids, PUFAs, UACA, CTR, ABI, cartid echography, and ECG.	—

Measure

Time frame

1) All cause death, 2)Cardiovascular events (composite of cardiovascular death, non-fatal myocardial infarction, unstable angina pectoris, non-fatal ischemic stroke, hospitalization for heart failure, coronary revascularization, or hospitalization for peripheral artery disease), 3) Change in fasting glucose, HbA1c, body weight, insluin resistance and secretion, BNP, Hs-CRP, lipids, PUFAs, UACA, CTR, ABI, cartid echography, and ECG.

—

Countries

Japan

Contacts

Public ContactSatoru Kishi

Mitsui Memorial Hospital Division of diabetes

m980287@gmail.com03-3862-9111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026